Medication-assisted treatment works. The data is overwhelming: buprenorphine and methadone reduce opioid overdose deaths, improve treatment retention, and support long-term recovery more effectively than abstinence-only approaches. This isn't debatable — it's established science.
And yet, the majority of people with opioid use disorder in the United States still don't have access to MAT. The gap between what the evidence says and what patients can actually receive remains one of the most consequential failures in American healthcare.
Why the gap persists
The barriers are both structural and cultural. On the structural side, there aren't enough providers. Despite regulatory changes making it easier to prescribe buprenorphine, the number of physicians actually doing so remains far below what's needed, particularly in rural areas and underserved communities.
On the cultural side, stigma — both within the medical profession and in society broadly — continues to suppress adoption. Too many treatment programs still operate from ideological frameworks rather than evidence-based ones.
What entrepreneurs can do
This is why I founded Outreach Recovery. The vision wasn't just to provide treatment — it was to build a model that could scale. Evidence-based protocols, compassionate care teams, and operational infrastructure that can be replicated across locations.
Addiction medicine needs more physician-entrepreneurs who are willing to build, not just treat. The clinical evidence is there. The patient need is there. What's been missing is the operational and business sophistication to deliver MAT at the scale the crisis demands.